Stay updated on Dabrafenib/Trametinib in BRAF V600E+ Rare Cancers Clinical Trial

Sign up to get notified when there's something new on the Dabrafenib/Trametinib in BRAF V600E+ Rare Cancers Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Dabrafenib/Trametinib in BRAF V600E+ Rare Cancers Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    Revision: v3.5.4 was added, replacing the previous v3.5.3. This indicates a minor, behind-the-scenes update to the page's template and system.
    Difference
    0.0%
    Check dated 2026-05-17T10:02:47.000Z thumbnail image
  3. Check
    18 days ago
    No Change Detected
  4. Check
    25 days ago
    No Change Detected
  5. Check
    32 days ago
    Change Detected
    Summary
    This update reflects a minor site/version revision change, updating the displayed ClinicalTrials.gov release version from v3.5.2 to v3.5.3.
    Difference
    0.0%
    Check dated 2026-04-25T18:39:41.000Z thumbnail image
  6. Check
    39 days ago
    Change Detected
    Summary
    Revision updated from v3.5.0 to v3.5.2.
    Difference
    0.0%
    Check dated 2026-04-18T13:32:34.000Z thumbnail image
  7. Check
    61 days ago
    Change Detected
    Summary
    Added 'Thyroid gland undifferentiated (anaplastic) carcinoma' as a terminology/MeSH term in the study record. This update appears to be a metadata/terminology addition rather than a change to core study content.
    Difference
    0.0%
    Check dated 2026-03-28T03:04:48.000Z thumbnail image
  8. Check
    68 days ago
    Change Detected
    Summary
    Revision updated from v3.4.3 to v3.5.0 in the site footer.
    Difference
    0.0%
    Check dated 2026-03-21T00:33:11.000Z thumbnail image
  9. Check
    82 days ago
    Change Detected
    Summary
    Revision history shows the addition of Revision: v3.4.3 and deletion of Revision: v3.4.2. This change is a metadata update and does not alter study content, eligibility criteria, results, or user-facing functionality.
    Difference
    0.0%
    Check dated 2026-03-06T18:19:58.000Z thumbnail image

Stay in the know with updates to Dabrafenib/Trametinib in BRAF V600E+ Rare Cancers Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Dabrafenib/Trametinib in BRAF V600E+ Rare Cancers Clinical Trial page.